LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 113

Search options

  1. Article ; Online: Local Immunoradiotherapy in Patients With Metastatic Soft-Tissue Sarcoma-Reply.

    Seo, Yongwoo David / Pollack, Seth M

    JAMA oncology

    2024  

    Language English
    Publishing date 2024-04-11
    Publishing country United States
    Document type Journal Article
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2024.0311
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Pushing forward in sarcoma with a new TCR targeting NY-ESO-1.

    Al-Marayaty, Rusul / Pollack, Seth M

    Cell reports. Medicine

    2023  Volume 4, Issue 8, Page(s) 101159

    Abstract: A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al. ...

    Abstract A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al.
    MeSH term(s) Humans ; Receptors, Antigen, T-Cell ; Antigens, Neoplasm ; Sarcoma/therapy ; Soft Tissue Neoplasms
    Chemical Substances Receptors, Antigen, T-Cell ; Antigens, Neoplasm
    Language English
    Publishing date 2023-08-16
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2666-3791
    ISSN (online) 2666-3791
    DOI 10.1016/j.xcrm.2023.101159
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Immunotherapy and Radiotherapy Combinations for Sarcoma.

    Zhang, Qian S / Hayes, John P / Gondi, Vinai / Pollack, Seth M

    Seminars in radiation oncology

    2024  Volume 34, Issue 2, Page(s) 229–242

    Abstract: Sarcomas are a heterogeneous group of bone and soft tissue tumors. Survival outcomes for advanced (unresectable or metastatic) disease remain poor, so therapeutic improvements are needed. Radiotherapy plays an integral role in the neoadjuvant and ... ...

    Abstract Sarcomas are a heterogeneous group of bone and soft tissue tumors. Survival outcomes for advanced (unresectable or metastatic) disease remain poor, so therapeutic improvements are needed. Radiotherapy plays an integral role in the neoadjuvant and adjuvant treatment of localized disease as well as in the treatment of metastatic disease. Combining radiotherapy with immunotherapy to potentiate immunotherapy has been used in a variety of cancers other than sarcoma, and there is opportunity to further investigate combining immunotherapy with radiotherapy to try to improve outcomes in sarcoma. In this review, we describe the diversity of the tumor immune microenvironments for sarcomas and describe the immunomodulatory effects of radiotherapy. We discuss studies on the timing of radiotherapy relative to immunotherapy and studies on the radiotherapy dose and fractionation regimen to be used in combination with immunotherapy. We describe the impact of radiotherapy on the tumor immune microenvironment. We review completed and ongoing clinical trials combining radiotherapy with immunotherapy for sarcoma and propose future directions for studies combining immunotherapy with radiotherapy in the treatment of sarcoma.
    MeSH term(s) Humans ; Sarcoma/radiotherapy ; Sarcoma/drug therapy ; Soft Tissue Neoplasms/drug therapy ; Combined Modality Therapy ; Neoadjuvant Therapy ; Immunotherapy ; Tumor Microenvironment
    Language English
    Publishing date 2024-02-27
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1146999-7
    ISSN 1532-9461 ; 1053-4296
    ISSN (online) 1532-9461
    ISSN 1053-4296
    DOI 10.1016/j.semradonc.2023.12.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3654: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.

    Pollack, Seth M

    Expert review of vaccines

    2017  Volume 17, Issue 2, Page(s) 107–114

    Abstract: Introduction: Synovial Sarcoma (SS) and Myxoid Round Cell Liposarcoma (MRCL) are devastating sarcoma subtypes with few treatment options and poor outcomes in the advanced setting. However, both these diseases may be ideal for novel immunotherapies ... ...

    Abstract Introduction: Synovial Sarcoma (SS) and Myxoid Round Cell Liposarcoma (MRCL) are devastating sarcoma subtypes with few treatment options and poor outcomes in the advanced setting. However, both these diseases may be ideal for novel immunotherapies targeting the cancer-testis antigen, NY-ESO-1.
    Areas covered: In this review, we discuss the novel NY-ESO-1 targeted vaccine regimen, CMB305. This regimen uses a unique integration-deficient, dendritic-cell targeting lentiviral vector from the ZVex® platform, LV305, in order to prime NY-ESO-1 specific T cells. LV305 has single agent activity, and, in one case, caused a durable partial response in a refractory SS patient. CMB305 also includes a boost from a NY-ESO-1 protein vaccine given along with a potent toll-like-4 receptor agonist, glycopyranosyl lipid A. CMB305 induces NY-ESO-1 specific T cell responses in both SS and MRC patients and these patients had excellent overall survival (OS) outcomes in the initial phase I study.
    Expert commentary: CMB305 is a therapeutic vaccine regimen targeting NY-ESO-1 based on the lentiviral vaccine vector, LV305. Phase I studies have proven this vaccine is active immunologically. Data suggesting this vaccine may improve OS for SS and MRCL patients is exciting but early, and on-going work is testing the impact of CMB305 on patient outcomes.
    MeSH term(s) Animals ; Cancer Vaccines/administration & dosage ; Cancer Vaccines/immunology ; Humans ; Immunotherapy/methods ; Liposarcoma, Myxoid/immunology ; Liposarcoma, Myxoid/therapy ; Sarcoma, Synovial/immunology ; Sarcoma, Synovial/therapy ; Survival Rate ; Treatment Outcome
    Chemical Substances Cancer Vaccines
    Language English
    Publishing date 2017-12-27
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 2181284-6
    ISSN 1744-8395 ; 1476-0584
    ISSN (online) 1744-8395
    ISSN 1476-0584
    DOI 10.1080/14760584.2018.1419068
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6077: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Combination Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma-Reply.

    Wagner, Michael J / Cranmer, Lee D / Pollack, Seth M

    JAMA oncology

    2021  Volume 7, Issue 3, Page(s) 465–466

    MeSH term(s) Anthracyclines ; Antibodies, Monoclonal, Humanized/adverse effects ; Doxorubicin/adverse effects ; Humans ; Sarcoma/drug therapy
    Chemical Substances Anthracyclines ; Antibodies, Monoclonal, Humanized ; Doxorubicin (80168379AG) ; pembrolizumab (DPT0O3T46P)
    Language English
    Publishing date 2021-02-03
    Publishing country United States
    Document type Letter ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2020.7873
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma.

    Lynch, Meghan M / Alexiev, Borislav A / Schroeder, Brett A / Pollack, Seth M

    Current treatment options in oncology

    2022  Volume 23, Issue 12, Page(s) 1861–1876

    Abstract: Opinion statement: While no PD-1 inhibitor has been FDA approved for use in sarcoma or proven efficacious in a randomized trial, the use of single agent PD-1 inhibitors is standard-of-care and recommended by the NCCN guidelines in certain specific ... ...

    Abstract Opinion statement: While no PD-1 inhibitor has been FDA approved for use in sarcoma or proven efficacious in a randomized trial, the use of single agent PD-1 inhibitors is standard-of-care and recommended by the NCCN guidelines in certain specific subtypes and situations. Even while the role of immunotherapy is still being defined in sarcoma, there is rising interest in combinations of PD-1 inhibitors with standard-of-care treatments, especially chemotherapy. Recently, several early phase trials have suggested potential benefits for chemotherapy in combination with PD-1 inhibitors. Although some physicians are already combining PD-1 inhibitors and chemotherapy for sarcoma off-label in the community, we believe more data is necessary. We support further evaluation of these combinations in well-designed clinical trials.
    MeSH term(s) Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Sarcoma/drug therapy ; Immunotherapy ; B7-H1 Antigen
    Chemical Substances Immune Checkpoint Inhibitors ; B7-H1 Antigen
    Language English
    Publishing date 2022-11-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057351-0
    ISSN 1534-6277 ; 1527-2729
    ISSN (online) 1534-6277
    ISSN 1527-2729
    DOI 10.1007/s11864-022-01036-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5523: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas.

    Lien, Irvin C / Pollack, Seth M

    Translational gastroenterology and hepatology

    2018  Volume 3, Page(s) 4

    Language English
    Publishing date 2018-01-15
    Publishing country China
    Document type Editorial ; Comment
    ISSN 2415-1289
    ISSN 2415-1289
    DOI 10.21037/tgh.2017.12.09
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Targeting cancer testis antigens in synovial sarcoma.

    Mitchell, Geoffrey / Pollack, Seth M / Wagner, Michael J

    Journal for immunotherapy of cancer

    2021  Volume 9, Issue 6

    Abstract: Synovial sarcoma (SS) is a rare cancer that disproportionately affects children and young adults. Cancer testis antigens (CTAs) are proteins that are expressed early in embryonic development, but generally not expressed in normal tissue. They are ... ...

    Abstract Synovial sarcoma (SS) is a rare cancer that disproportionately affects children and young adults. Cancer testis antigens (CTAs) are proteins that are expressed early in embryonic development, but generally not expressed in normal tissue. They are aberrantly expressed in many different cancer types and are an attractive therapeutic target for immunotherapies. CTAs are expressed at high levels in SS. This high level of CTA expression makes SS an ideal cancer for treatment strategies aimed at harnessing the immune system to recognize aberrant CTA expression and fight against the cancer. Pivotal clinical trials are now underway, with the potential to dramatically alter the landscape of SS management and treatment from current standards of care. In this review, we describe the rationale for targeting CTAs in SS with a focus on NY-ESO-1 and MAGE-A4, the current state of vaccine and T-cell receptor-based therapies, and consider emerging opportunities for future development.
    MeSH term(s) Antigens, Neoplasm/metabolism ; Cancer Vaccines/pharmacology ; Cancer Vaccines/therapeutic use ; Child ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Membrane Proteins/metabolism ; Neoplasm Proteins/metabolism ; Receptors, Antigen, T-Cell/metabolism ; Sarcoma, Synovial/immunology ; Sarcoma, Synovial/therapy ; T-Lymphocytes/transplantation ; Up-Regulation/drug effects ; Young Adult
    Chemical Substances Antigens, Neoplasm ; CTAG1B protein, human ; Cancer Vaccines ; MAGEA4 protein, human ; Membrane Proteins ; Neoplasm Proteins ; Receptors, Antigen, T-Cell
    Language English
    Publishing date 2021-06-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2020-002072
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Immunotherapy of sarcomas with modified T cells.

    Mahalingam, Preethika / Julve, Maximilian / Huang, Paul / Furness, Andrew J S / Pollack, Seth M / Jones, Robin L

    Current opinion in oncology

    2022  Volume 34, Issue 4, Page(s) 362–370

    Abstract: Purpose of review: To summarize the development of modified T-cell therapies in sarcomas and discuss relevant published and ongoing clinical trials to date.: Recent findings: Numerous clinical trials are underway evaluating tumor-specific chimeric ... ...

    Abstract Purpose of review: To summarize the development of modified T-cell therapies in sarcomas and discuss relevant published and ongoing clinical trials to date.
    Recent findings: Numerous clinical trials are underway evaluating tumor-specific chimeric antigen receptor T cells and high affinity T-cell receptor (TCR)-transduced T cells in sarcomas. Notably, translocation-dependent synovial sarcoma and myxoid/round cell liposarcoma are the subject of several phase II trials evaluating TCRs targeting cancer testis antigens New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and melanoma antigen-A4 (MAGE A4), and response rates of up to 60% have been observed for NY-ESO-1 directed, modified T cells in synovial sarcoma. Challenges posed by modified T-cell therapy include limitations conferred by HLA-restriction, non-immunogenic tumor microenvironments (TME), aggressive lymphodepletion and immune-mediated toxicities restricting coinfusion of cytokines.
    Summary: Cellular therapy to augment the adaptive immune response through delivery of modified T cells is an area of novel therapeutic development in sarcomas where a reliably expressed, ubiquitous target antigen can be identified. Therapeutic tools to improve the specificity, signaling, proliferation and persistence of modified TCRs and augment clinical responses through safe manipulation of the sarcoma TME will be necessary to harness the full potential of this approach.
    MeSH term(s) Adult ; Antigens, Neoplasm ; Esophageal Neoplasms ; Esophageal Squamous Cell Carcinoma ; Humans ; Immunotherapy ; Male ; Receptors, Antigen, T-Cell ; Sarcoma, Synovial/pathology ; Sarcoma, Synovial/therapy ; Soft Tissue Neoplasms ; T-Lymphocytes ; Tumor Microenvironment
    Chemical Substances Antigens, Neoplasm ; Receptors, Antigen, T-Cell
    Language English
    Publishing date 2022-07-13
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1049384-0
    ISSN 1531-703X ; 1040-8746
    ISSN (online) 1531-703X
    ISSN 1040-8746
    DOI 10.1097/CCO.0000000000000843
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3046: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Treatment of refractory gastrointestinal stromal tumor using pazopanib.

    Lien, Irvin C / Pollack, Seth M

    Translational gastroenterology and hepatology

    2016  Volume 1, Page(s) 86

    Language English
    Publishing date 2016-11-29
    Publishing country China
    Document type Journal Article ; Comment
    ISSN 2415-1289
    ISSN 2415-1289
    DOI 10.21037/tgh.2016.11.01
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top